China Medical System Holdings Limited (HKG:0867)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 19.30B |
| Revenue (ttm) | 7.95B |
| Net Income (ttm) | 1.72B |
| Shares Out | 2.44B |
| EPS (ttm) | 0.71 |
| PE Ratio | 11.14 |
| Forward PE | 10.92 |
| Dividend | 0.29 (3.70%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 18,644,000 |
| Average Volume | 10,183,103 |
| Open | 7.71 |
| Previous Close | 7.75 |
| Day's Range | 7.68 - 8.22 |
| 52-Week Range | 6.23 - 10.28 |
| Beta | 0.90 |
| RSI | 50.86 |
| Earnings Date | Mar 14, 2025 |
About HKG:0867
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of ch... [Read more]
Financial Performance
In 2024, HKG:0867's revenue was 7.47 billion, a decrease of -6.79% compared to the previous year's 8.01 billion. Earnings were 1.62 billion, a decrease of -32.54%.
Financial numbers in CNY Financial StatementsNews
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
On Wednesday, Alpha Cognition Inc. (NASDAQ: ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for the development, manufacturing, and commercialization of Zun...